Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17161635 | 0.86 | CA12 (0.62) | ALDH1A1MEN1KMT2AHPGDHTT | |
| SCHEMBL6342125 | 0.86 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AADRB2POLB | |
| SCHEMBL1020427 | 0.85 | MAPT (0.57) | ALDH1A1MEN1KMT2AHPGDMAPT | |
| SCHEMBL31371201 | 0.85 | MAPT (0.57) | ALDH1A1MEN1KMT2AHPGDMAPT | |
| SCHEMBL11284780 | 0.85 | AKT1 (0.50) | ALDH1A1MEN1KMT2AADRB2POLB | |
| SCHEMBL14003532 | 0.84 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2AADRB2POLB | |
| SCHEMBL5119766 | 0.83 | CREBBP (0.62) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL13461886 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AADRB2POLB | |
| SCHEMBL8649778 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AADRB2POLB | |
| SCHEMBL7093110 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AADRB2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2966079-B1 | PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-2966079-B1 | PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-11-24 | — | — | EP | disclosed |
| CN-109748910-B | Quinazolinone compound, preparation method and medical application thereof | 徐州医科大学 | 2021-04-30 | — | — | CN | disclosed |
| CN-109748910-A | A kind of quianzolinones, preparation method and medical usage | 徐州医科大学 | 2019-05-14 | — | — | CN | disclosed |
| US-9796732-B2 | Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796732-B2 | Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796732-B2 | Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2017-10-24 | — | — | US | disclosed |
| EP-2966079-A1 | PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966079-A1 | PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2016-01-13 | — | — | EP | disclosed |
| US-20150368274-A1 | Pyridopyrimidine Or Pyrimidopyrimidine Compound, Prepration Method, Pharmaceutical Composition, And Use Thereof | FUDAN UNIVERSITY (CN) | 2015-12-24 | — | — | US | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0545376-B1 | Guanidino thiazoles and their use as H2-receptor antagonist | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5532258-A | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0545376-A1 | Guanidino thiazoles and their use as H2-receptor antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368274-A1 | Pyridopyrimidine Or Pyrimidopyrimidine Compound, Prepration Method, Pharmaceutical Composition, And Use Thereof | MTOR, PIK3CA, RICTOR | ALDH1A1 2906/4885MEN1 2211/4885KMT2A 4095/4885 |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | ALDH1A1 827/4885MEN1 4060/4885KMT2A 2392/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | ALDH1A1 385/4885MEN1 794/4885KMT2A 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.